The effect of TCAs on CYP2D6 activity in vivo

被引：0
|
作者：
Szewczuk-Boguslawska, M. [1 ]
Kiejna, A. [1 ]
Beszlej, J. [1 ]
Orzechowska-Juzwenko, K. [1 ]
机构：
[1] Univ Med, Wroclaw, Poland
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S251 / S251
页数：1
相关论文
共 50 条
  • [1] Doxepin inhibits CYP2D6 activity in vivo
    Szewczuk-Boguslawska, M
    Kiejna, A
    Beszlej, JA
    Orzechowska-Juzwenko, K
    Milejski, P
    POLISH JOURNAL OF PHARMACOLOGY, 2004, 56 (04): : 491 - 494
  • [2] In vivo indices of enzyme activity:: the effect of renal impairment on the assessment of CYP2D6 activity
    Rostami-Hodjegan, A
    Funck-Brentano, C
    Kroemer, HK
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) : 577 - 578
  • [3] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [4] In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
    Hertz, Daniel L.
    Snavely, Anna C.
    McLeod, Howard L.
    Walko, Christine M.
    Ibrahim, Joseph G.
    Anderson, Steven
    Weck, Karen E.
    Magrinat, Gustav
    Olajide, Oludamilola
    Moore, Susan
    Raab, Rachel
    Carrizosa, Daniel R.
    Corso, Steven
    Schwartz, Garry
    Peppercorn, Jeffrey M.
    Evans, James P.
    Jones, David R.
    Desta, Zeruesenay
    Flockhart, David A.
    Carey, Lisa A.
    Irvin, William J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) : 1122 - 1130
  • [5] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [6] In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity
    Rostami-Hodjegan, A
    Kroemer, HK
    Tucker, GT
    PHARMACOGENETICS, 1999, 9 (03): : 277 - 286
  • [7] Effect of different alleles on CYP2D6 activity.
    Borges, S
    Jones, DR
    Bermes, A
    Skaar, TC
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P25 - P25
  • [8] Effect of sodium ozagrel on the activity of rat CYP2D6
    Wu, Hong
    Yu, Weijiang
    Huang, Lijun
    Wang, Jing
    Tang, Xiaobo
    Yang, Wei
    Liu, Yan
    Yu, Huiyan
    Zhu, Daling
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 573 (1-3) : 55 - 59
  • [9] The antitussive effect of dextromethorphan in relation to CYP2D6 activity
    Manap, RA
    Wright, CE
    Gregory, A
    Rostami-Hodjegan, A
    Meller, ST
    Kelm, GR
    Lennard, MS
    Tucker, GT
    Morice, AH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) : 382 - 387
  • [10] Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity
    Ducharme, J
    Abdullah, S
    Wainer, IW
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 678 (01): : 113 - 128
12345